DiaMedica Therapeutics (DMAC) Options Chain & Prices $7.06 +0.42 (+6.33%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$6.95 -0.11 (-1.56%) As of 10/13/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Options Chain Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DMAC Put and Call Options List 4/17/2026 1/16/2026 11/21/2025 10/17/2025 Options Date Put and Call Options Put Options Call Options Options Type All In The Money Out of The Money Moneyness With Volume Without Volume All Volume Strike Price Min Strike Price Max Export to Excel ExpiresStrike PriceClose PricePut/CallVolumeVolume AskVolume BidOpen InterestImplied VolatilityDeltaTrades10/17/2025$7.50$0.153Call1353055626(-96)99.15% (-2.72%)0.3332299End-of-day options data provided by Trade Alert and Intrinio. Related Companies and Tools Related Companies Avadel Pharmaceuticals Options Data Janux Therapeutics Options Data Arcus Biosciences Options Data Stoke Therapeutics Options Data Syndax Pharmaceuticals Options Data Xeris Biopharma Options Data Taysha Gene Therapies Options Data Nuvation Bio Options Data Ardelyx Options Data Amphastar Pharmaceuticals Options Data Options Chain Tools Short Interest TrackerShort Interest IncreasesShort Interest DecreasesUnusual Call VolumeUnusual Put Volume This page (NASDAQ:DMAC) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredIs your money positioned for what’s coming?The 7 red flags Wall Street won’t talk aboutAmerican Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
